The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Altered Expression of Diabetes-Related Genes in Alzheimer's Disease Brains: The Hisayama Study
Open accessAbstract
Diabetes mellitus (DM) is considered to be a risk factor for dementia including Alzheimer's disease (AD). However, the molecular mechanism underlying this risk is not well understood. We examined gene expression profiles in postmortem human brains donated for the Hisayama study. Three-way analysis of variance of microarray data from frontal cortex, temporal cortex, and hippocampus was performed with the presence/absence of AD and vascular dementia, and sex, as factors. Comparative analyses of expression changes in the brains of AD patients and a mouse model of AD were also performed. Relevant changes in gene expression identified by microarray analysis were validated by quantitative real-time reverse-transcription polymerase chain reaction and western blotting. The hippocampi of AD brains showed the most significant alteration in gene expression profile. Genes involved in noninsulin-dependent DM and obesity were significantly altered in both AD brains and the AD mouse model, as were genes related to psychiatric disorders and AD. The alterations in the expression profiles of DM-related genes in AD brains were independent of peripheral DM-related abnormalities. These results indicate that altered expression of genes related to DM in AD brains is a result of AD pathology, which may thereby be exacerbated by peripheral insulin resistance or DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 2×
“…protein tau (MAPT) (AT8, mouse monoclonal, 1:500; Innogenetics, Belgium) and the assessment of AD pathology was conducted according to the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) guidelines (Mirra et al. 1991) and the Braak stage (Braak and Braak 1991).”
BackgroundMethodGlobal prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Self-citationConsortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G. G., & Heyman, A. (2002) · Principles and Practice of Geriatric Psychiatry · doi:10.1002/0470846410.ch42(iii · Cited by 2,410
Azevedo, F. A. C., Carvalho, L. R. B., Grinberg, L. T., Farfel, J. M., Ferretti, R. E. L., Leite, R. E. P., Filho, W. J., Lent, R., & Herculano‐Houzel, S. (2009) · Journal of Comparative Neurology · doi:10.1002/cne.21974 · Cited by 2,337 · cited 2×
“…markers, including RBFOX3 encoding NeuN (Dredge and Jensen 2011), which is expressed in about 68% of cells in the gray matter of the adult cerebral cortex (Azevedo et al. 2009), were consistently decreased in AD brains relative to the levels in non-AD brains, most significantly in the hippocampus.”
BackgroundSteen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703
Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J., & Guénette, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230450100 · Cited by 1,286
Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
Cited by
Grubman, A., Chew, G., Ouyang, J. F., Sun, G., Choo, X. Y., McLean, C., Simmons, R. K., Buckberry, S., Vargas-Landin, D. B., Poppe, D., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0539-4 · Cited by 956
Evidence for brain glucose dysregulation in Alzheimer's disease
An, Y., Varma, V. R., Varma, S., Casanova, R., Dammer, E., Pletnikova, O., Chia, C. W., Egan, J. M., Ferrucci, L., Troncoso, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.09.011 · Cited by 507
Blázquez, E., Velázquez, E., Hurtado-Carneiro, V., & Ruiz-Albusac, J. M. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00161 · Cited by 491
Xu, M., Zhang, D., Luo, R., Wu, Y., Zhou, H., Kong, L., Bi, R., & Yao, Y. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.08.012 · Cited by 296
Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment
Folch, J., Petrov, D., Ettcheto, M., Abad, S., Sánchez-López, E., García, M. L., Olloquequi, J., Beas-Zarate, C., Auladell, C., & Camins, A. (2016) · Neural Plasticity · doi:10.1155/2016/8501693 · Cited by 270
Neuner, S. M., Heuer, S. E., Huentelman, M. J., O’Connell, K. M. S., & Kaczorowski, C. C. (2019) · Neuron · doi:10.1016/j.neuron.2018.11.040 · Cited by 202
Lima, J. E. B. F., Moreira, N. C. S., & Sakamoto-Hojo, E. T. (2022) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2021.503437 · Cited by 203
Kelley, K. W., Nakao-Inoue, H., Molofsky, A. V., & Oldham, M. C. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0216-z · Cited by 198
PARK2 enhancement is able to compensate mitophagy alterations found in sporadic Alzheimer's disease
Martín-Maestro, P., Gargini, R., Perry, G., Avila, J., & García-Escudero, V. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddv616 · Cited by 184
Petrov, D., Pedrós, I., Artiach, G., Sureda, F. X., Barroso, E., Pallàs, M., Casadesús, G., Beas-Zarate, C., Carro, E., Ferrer, I., et al. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.05.004 · Cited by 163
Castillo, E., Leon, J., Mazzei, G., Abolhassani, N., Haruyama, N., Saito, T., Saido, T., Hokama, M., Iwaki, T., Ohara, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17999-3 · Cited by 158
Self-citationAbolhassani, N., Leon, J., Sheng, Z., Oka, S., Hamasaki, H., Iwaki, T., & Nakabeppu, Y. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.05.005 · Cited by 140
Self-citationAge and Alzheimer’s disease gene expression profiles reversed by the glutamate modulator riluzole
Pereira, A. C., Gray, J. D., Kogan, J. F., Davidson, R. L., Rubin, T. G., Okamoto, M., Morrison, J. H., & McEwen, B. S. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.33 · Cited by 116
Hargis, K. E., & Blalock, E. M. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.05.007 · Cited by 90
Kodam, P., Sai Swaroop, R., Pradhan, S. S., Sivaramakrishnan, V., & Vadrevu, R. (2023) · Scientific Reports · doi:10.1038/s41598-023-30892-6 · Cited by 82
Oka, S., Leon, J., Sakumi, K., Ide, T., Kang, D., LaFerla, F. M., & Nakabeppu, Y. (2016) · Scientific Reports · doi:10.1038/srep37889 · Cited by 78
Self-citationLanke, V., Moolamalla, S. T. R., Roy, D., & Vinod, P. K. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00153 · Cited by 76
RAGE-TXNIP axis drives inflammation in Alzheimer’s by targeting Aβ to mitochondria in microglia
Sbai, O., Djelloul, M., Auletta, A., Ieraci, A., Vascotto, C., & Perrone, L. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-04758-0 · Cited by 72
Simon, M. J., Wang, M. X., Murchison, C. F., Roese, N. E., Boespflug, E. L., Woltjer, R. L., & Iliff, J. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-30779-x · Cited by 71
Martiskainen, H., Viswanathan, J., Nykänen, N.-P., Kurki, M., Helisalmi, S., Natunen, T., Sarajärvi, T., Kurkinen, K. M. A., Pursiheimo, J.-P., Rauramaa, T., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.09.003 · Cited by 70
The three-dimensional landscape of cortical chromatin accessibility in Alzheimer’s disease
Bendl, J., Hauberg, M. E., Girdhar, K., Im, E., Vicari, J. M., Rahman, S., Fernando, M. B., Townsley, K. G., Dong, P., Misir, R., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01166-7 · Cited by 65
Karunakaran, K. B., Chaparala, S., Lo, C. W., & Ganapathiraju, M. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-72024-4 · Cited by 56
Satoh, J.-I., Yamamoto, Y., Asahina, N., Kitano, S., & Kino, Y. (2014) · Disease Markers · doi:10.1155/2014/123165 · Cited by 53
Oka, S., Leon, J., Sakumi, K., Abolhassani, N., Sheng, Z., Tsuchimoto, D., LaFerla, F. M., & Nakabeppu, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-84640-9 · Cited by 51
Self-citationFolch, J., Patraca, I., Martínez, N., Pedrós, I., Petrov, D., Ettcheto, M., Abad, S., Marin, M., Beas-Zarate, C., & Camins, A. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.05.002 · Cited by 48
Guanosine monophosphate reductase 1 is a potential therapeutic target for Alzheimer’s disease
Liu, H., Luo, K., & Luo, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-21256-6 · Cited by 42
Down‐regulation of MET in hippocampal neurons of Alzheimer's disease brains
Hamasaki, H., Honda, H., Suzuki, S. O., Hokama, M., Kiyohara, Y., Nakabeppu, Y., & Iwaki, T. (2014) · Neuropathology · doi:10.1111/neup.12095 · Cited by 33
Self-citationPark, J.-H., Park, I., Youm, E. M., Lee, S., Park, J.-H., Lee, J., Lee, D. Y., Byun, M. S., Lee, J. H., Yi, D., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01412-9 · Cited by 30
Sanfilippo, C., Castrogiovanni, P., Imbesi, R., & Di Rosa, M. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01667-9 · Cited by 26
Finney, C. A., Delerue, F., Gold, W. A., Brown, D. A., & Shvetcov, A. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.12.018 · Cited by 22
Iketani, R., Ohno, K., Kawasaki, Y., Matsumoto, K., Yamada, H., & Kishino, S. (2018) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00929 · Cited by 10
Metadata
- Authors
- Hokama, M., Oka, S., Leon, J., Ninomiya, T., Honda, H., Sasaki, K., Iwaki, T., Ohara, T., Sasaki, T., LaFerla, F. M., Kiyohara, Y., & Nakabeppu, Y.
- Venue
- Cerebral Cortex
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-04-17
- Volume
- 24
- Issue
- 9
- Pages
- 2476-2488
- ISSN
- 1047-3211 (ISSN-L)
- 1460-2199
- OpenAlex
- W2150730731
- Cited by
- 322
- References
- 51
- FWCI
- 10.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.